- 作者：Á ; ngel Dí ; az Rodrí ; guez ; med015917@yahoo.es ; Adalberto Serrano Cumplido ; David Fierro Gonzá ; lez ; Luis Alberto Rodrí ; guez Arroyo ; Francisco-Javier Garcí ; a-Norro Herreros ; Serafí ; n de Abajo Olea ; Isidro Ló ; pez Rodrí ; guez ; Josefa Marí ; a Panisello Royo ; Jose Carlos Minguez Villar ; Jesú ; s Palomo del Arco ; Rafael Colá ; s Chacartegui ; Vicente Pascual Fuster ; Juan Carlos Verdes-Montenegro Atalaya ; en representació ; n del Grupo de Lí ; pidos de SEMERGEN
- 关键词：Pitavastina ; Tratamiento farmacoló ; gico ; Hipolipemiante ; Eficacia ; Perfil Lipí ; dico ; Seguridad
- 刊名：Cl¨ªnica e Investigaci¨®n en Arteriosclerosis
- 出版年：2012
- 出版时间：January-February, 2012
- 年：2012
- 卷：24
- 期：1
- 页码：30-39
- 全文大小：341 K
Statins decrease LDLc levels significantly and reduce the risk of cardiovascular disease (CVD). There is no lower threshold from which the lipid-lowering effect is not beneficial. Current guidelines recommend LDLc levels below 100 mg/dL in patients with established CVD and less than 70-80 mg/dL in very high risk patients. In patients at LDLc target, the risk of major cardiovascular events is only reduced about one third, remaining an important residual risk, due in part to atherogenic dyslipidemia and its components. It therefore follows that the most effective statins have a general lipid profile and a strong reduction in LDLc.
Pitavastatin belongs to the statin group that fulfils the above-mentioned requirements. Pitavastatin is a synthetic statin, moderately lipophilic with a good oral absorption and low risk of drug-food interaction and a high biodisponibility. It produces an important change in the overall lipid profile with a significant reduction in LDLc levels. Pitavastatin, at equivalent doses to other strong statins, gets decreases in LDLc up to 45 % , about 90 % of patients treated with pitavastatin reach the EAS treatment target, it increases HDLc up to 14 % (even to 24,6 % in patients with a very high level of HDLc), decreases TG by 17 % and positively changes the rest of other lipid parameters, in the long term. Pitavastatin is not metabolized in significant by CYP450 3A4, therefore it has a low drug-drug interaction profile, especially in the polymedicated patients (elderly, diabetic, nephropathic, hypertensive, heart disease and patients with a high risk cardiovascular). Also, pitavastatin has statins class pleiotropic effects and specific ones effects about carbohydrate metabolism, glomerular filtration, adiponectin?beyond lipid lowering, which can be added to the reduction of residual risk. Pitavastatin is well tolerated, not toxicity and safety data are supported by a significant number of patients currently treated.